GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 03:43:10 2024-03-01 am EST 5-day change 1st Jan Change
1,654 GBX -0.62% Intraday chart for GSK plc -1.17% +13.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Up on Strong Earnings -- Health Care Roundup DJ
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo... Our Logo
GSK: Dr Jeannie Lee joins the Board of Directors CF
UK’s FTSE 100 Index Flat as Consumer Lending Grows MT
GSK Says California Zantac Case Reached Undisclosed Settlement MT
GSK: confidential settlement for Zantac in California CF
European Midday Briefing : Caution Ahead of Key U.S. Inflation Print Keeps Stocks in Check DJ
GSK avoids "protracted litigation" with Zantac settlement AN
Haleon Backs Views After Profit Rise on Robust Growth -- Update DJ
Haleon Backs Views After Profit Rise on Robust Growth DJ
UK's GSK Settles Zantac Lawsuit Set for April Trial in US MT
GSK confidentially settles another California Zantac lawsuit RE
GSK Names Jeannie Lee As Non-Executive Director RE
GSK Statement On Zantac (Ranitidine) Litigation RE
Consumer health giant Haleon sees higher revenue in 2024 RE
GSK: 29 FEBRUARY 2024 STATEMENT: ZANTAC (RANITIDINE) LITIGATION… RE
GSK plc Appoints Jeannie Lee D to the Board of the Company as A Non-Executive Director CI
GSK : Berenberg reaffirms its Buy rating ZD
GSK Says Phase 3 Trial in Uncomplicated Urogenital Gonorrhea Meets Primary Endpoint MT
GSK: RSV VACCINE, AREXVY, ACCEPTED FOR REVIEW BY HEALTH CANADA F… RE
GSK plc Announces Positive Headline Results from EAGLE-1 Phase III Trial for Gepotidacin in Uncomplicated Urogenital Gonorrhoea (GC) CI
GSK: positive results in the treatment of gonorrhea CF
GSK gonorrhoea treatment achieves efficacy endpoint in latest trial AN
GSK's Oral Antibiotic Shows Non-inferiority in Late-stage Gonorrhea Study MT
GSK's gonorrhoea drug meets main goal in late-stage trial RE
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. The Company owns camlipixant, a selective P2X3 antagonist, which is in Phase III development for the treatment of refractory chronic cough (RCC).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
16.65 GBP
Average target price
19.51 GBP
Spread / Average Target
+17.20%
Consensus
  1. Stock
  2. Equities
  3. Stock GSK plc - London S.E.
  4. News GSK plc
  5. Jefferies Reduces GSK PT, Maintains Hold Recommendation
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW